An interventional study of threedimensional freehand ultrasound and instrumented spasticity assessment in Stroke, Spasticity and Equinovarus Foot, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven — 4 open to participants now, 4 under way, none of them phase 3. Stroke · Universitaire Ziekenhuizen KU Leuven.
Among the 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven, this one is one of 2 that started in 2025, is one of 6 with no phase, and was the 10th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →4 of the 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 65+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18–70
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 40 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 12 is below the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 23 across the 8 interventional studies, 76 across the 3 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Stroke by Universitaire Ziekenhuizen KU Leuven that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06767631Universitaire Ziekenhuizen KU LeuvenPilot Study on Muscle, Tendon, and Neural Changes Post-Botulinum Toxin Injections in Post-stroke Spastic Equinovarus | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Poststroke spasticity significantly impairs function, particularly through the development of pes equinovarus. Botulinum toxin A (BoNT) injections into the medial gastrocnemius (MG) are a first-line treatment. Treatment outcomes and long-term responses to interventions can vary significantly between individual patients. Additionally, there is increasing concern about potential adverse effects on muscle morphology. Further research is essential to optimize treatment strategies and improve long-term outcomes in this population. Three-dimensional freehand ultrasound (3DfUS) and instrumented spasticity assessment (ISA) are two recently developed techniques that enable the evaluation of changes in muscle, tendon, and neural properties following BoNT injections for post-stroke spastic equinovarus. These methods hold promise for providing new insights into treatment effects. Before implementing these techniques in large-scale studies, a pilot study is required for accurate sample size calculations for a prospective observational study. This study includes a protocol for a non-blinded, non-randomized open-label longitudinal pilot study. The study was approved by the European Medicines Agency ( EU CT Number 2024-513158-32) by the University Hospitals Leuven ethical committee (ID S68672). Standard deviations and effect sizes of outcome measures obtained longitudinally with 3DfUS and ISA before and after BoNT injection into MG will inform sample size calculations for future research.
TRIAL RATIONALE:
To conduct a pilot study as guidance for a future observational study to evaluate changes in muscle, tendon and neural properties after botulinum neurotoxin-A (BoNT) treatment of spastic equinovarus in first-ever stroke patients by using Three Dimensional freehand Ultrasound (3DfUS) and Instrumented Spasticity Assessment (ISA) with the aim of optimizing treatment algorithms and long-term response in this population.
TRIAL DESIGN:
Non-blinded, non-randomized open label, longitudinal pilot interventional clinical trial.
In total, 4 visits will be organised:
4 visits are organized according to the biological functioning of BoNT. These 4 visits also correspond to the standard clinical visits as they currently proceed when a patient is treated with BoNT. At baseline visit (week 0) and injection visit (week 6) we do not expect any changes in outcome parameters since no BoNT has been injected yet. The effect of BoNT has peak effects after 4-6 weeks and a duration of action between 2 and 6 months. At follow-up visit (week 10-12) and end-of-study visit (when BoNT is clinically elaborated, week 18-30) we expect corresponding changes in outcome parameters, respectively.
At each visit, 3DfUS measurements and ISA measurements will be performed on two muscles of both legs: 1) medial gastrocnemius muscle and 2) tibialis anterior muscle. The majority of US literature in the lower limb has focused on medial gastrocnemius. Additionally, these muscles are obvious candidates because of their functional importance in locomotion. Moreover, the medial gastrocnemius is a frequently injected muscle with BoNT, whereas tibialis anterior muscle is not. From a methodological perspective, both medial gastrocnemius and tibialis anterior are superficial and can be easily tracked by means of conventional US probes and EMG electrodes.
During visit 2, a pregnancy test will be conducted prior to the injection of Botulinum toxin. If the test is positive, the study will be discontinued, and the patient will not be treated with Botulinum toxin A.
Total duration of one visit will be 1.5 to 2 hours. All measurements of one visit take place on the same day. Measurements will be performed at the University Hospital Leuven.
For this study, stroke patients treated with BoNT for spastic equinovarus will be included. In particular stroke patients are patients that are being treated at the University Hospital, Leuven. The annual number of stroke patients seen in UZ Leuven is approximately 600 per year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study involves a single-arm, exploratory, longitudinal design focusing on first-time stroke patients with spastic equinovarus deformity. Participants will receive Botulinum Neurotoxin Type A (BoNT-A) injections targeting medial and lateral gastrocnemius muscle as well ass soleus muscle. The intervention aims to assess changes in muscle, tendon, and neural properties before and after treatment by using instrumented spasticity assessment and threedimensional freehand ultrasound
Diagnostic Test: threedimensional freehand ultrasound and instrumented spasticity assessment
To conduct a pilot study as guidance for a future observational study to evaluate changes in muscle, tendon and neural properties after botulinum neurotoxin-A (BoNT) treatment of spastic equinovarus in first-ever stroke patients by using Three Dimensional freehand Ultrasound (3DfUS) and Instrumented Spasticity Assessment (ISA) with the aim of optimizing treatment algorithms and long-term response in this population.
sample size calculation
To estimate the number of subjects to calculate an appropriate sample size for assessing changes in muscle, tendon and neural properties after BoNT treatment of spastic equinovarus in first-ever stroke patients by using 3DfUS and ISA in a future observational study. To calculate standard deviation and effect sizes of outcome measures obtained with 3DfUS and ISA in these patients.
Time frame: 2 years
muscle changes
Secondary outcome parameters measured by 3DfUS include muscle belly length for medial gastrocnemius muscle
Time frame: 2 years
neural changes
Secondary outcome parameters measured by ISA for slow stretch measured by ISA : maximal velocity of performance (Vmax \[deg/s\])
Time frame: 2 years
functional changes
Medical baseline data including age, gender, body mass index, time since stroke, stroke etiology, National Institute Health Stroke Scale \[15\], affected side, oral medication and adverse events will be collected at each visit from the patients medical file as they are part of standard of care:
Time frame: 2 years
muscle changes
Secondary outcome parameters measured by 3DfUS include tendon length for medial gastrocnemius muscle
Time frame: 2 years
muscle changes
Secondary outcome parameters measured by 3DfUS include mid-belly cross-sectional area for medial gastrocnemius muscle
Time frame: 2 years
muscle changes
Secondary outcome parameters measured by 3DfUS include muscle belly length for tibial anterior muscle
Time frame: 2 years
muscle changes
Secondary outcome parameters measured by 3DfUS mid-belly cross-sectional area for tibial anterior muscle
Time frame: 2 years
muscle changes
Secondary outcome parameters measured by 3DfUS include mean Echo Intensity for tibial anterior muscle
Time frame: 2 years
muscle changes
Secondary outcome parameters measured by 3DfUS include mean Echo Intensity for medial gastrocnemius muscle
Time frame: 2 years
neural changes
Secondary outcome parameters measured by ISA for slow stretch measured by ISA : range of motion \[deg\]
Time frame: 2 years
neural changes
Secondary outcome parameters measured by ISA for slow stretch measured by ISA: stiffness \[Nm/deg\]
Time frame: 2 years
neural changes
Secondary outcome parameters measured by ISA for slow stretch measured by ISA work \[J\] (area under the power-time curve).
Time frame: 2 years
neural changes
Secondary outcome parameters measured by ISA from the fast stretch: maximal velocity of performance (Vmax \[deg/s\])
Time frame: 2 years
neural changes
Secondary outcome parameters measured by ISA from the fast stretch: joint angle of catch \[deg\]
Time frame: 2 years
neural changes
Secondary outcome parameters measured by ISA from the fast stretch: angle of EMG threshold \[deg\]
Time frame: 2 years
neural changes
Secondary outcome parameters measured by ISA from the fast stretch: intensity of catch (power \[W\]; torque times angular velocity).
Time frame: 2 years
functional changes
Modified Asworth Scale
Time frame: 2 years
functional changes
Tardieu scale
Time frame: 2 years
functional changes
Barthel Index
Time frame: 2 years
functional changes
Functional Ambulation Categories
Time frame: 2 years
functional changes
the Rivermead Mobility Index
Time frame: 2 years
functional changes
Functional Independence Measure
Time frame: 2 years
functional changes
Fugl-Meyer scale
Time frame: 2 years
functional changes
Modified Rankin Scale
Time frame: 2 years
functional changes
5 Meter Timed Walking Test
Time frame: 2 years
functional changes
Motricity Index
Time frame: 2 years
functional changes
Five-Times Sit-to-Stand Test
Time frame: 2 years
functional changes
Gait analyses
Time frame: 2 years
Plan to share: No
Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 24 months is close to that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitaire Ziekenhuizen KU Leuven →